Glenmark receives USFDA approval for Nitroglycerin Sublingual Tablets

20 Sep 2017 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg, the generic version of Nitrostat Sublingual Tablets, 0.3 mg, 0.4 mg, and 0.6 mg, of Pfizer, Inc.

According to IMS Health sales data for the 12 month period ending July 2017, the Nitrostat Sublingual Tablets, 0.3 mg, 0.4 mg, and 0.6 mg market achieved annual sales of approximately $112.7 million.

Glenmark’s current portfolio consists of 125 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.



Glenmark Pharma Share Price

1996.60 0.70 (0.04%)
23-Jan-2026 11:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1630.80
Dr. Reddys Lab 1242.25
Cipla 1379.00
Zydus Lifesciences 887.80
Lupin 2152.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×